Cullinan Therapeutics, Inc. (CGEM): Results of Operations and Financial Condition
Cullinan Therapeutics, Inc. (CGEM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results CLN-978 (CD19 TCE) multi-dose regimen data in RA in Q3 2026 and SLE in Q4 2026; Phase 2 expansion studies to begin early 2027 Velinotamig (BCMA TCE) multi-dose regimen data in SLE in
How this was made
The 30-second read
Why it matters
Traders can update probability-weighted expectations for CGEM’s autoimmune and oncology assets based on (1) FDA End-of-Phase 1 clearance enabling a potentially registrational AML Phase 2 in Q3 2026, (2) planned multi-dose data releases in Q3/Q4 2026, and (3) a quantified cash position supporting operations into 2029.
Market read
The filing is a catalyst calendar update plus a funding runway datapoint, which can drive near-term biotech positioning around Phase 2 initiation and upcoming clinical data windows.
What to watch
Cash runway into 2029 is supportive, but dilution risk and trial execution timelines remain key; the NDA/PDUFA timeline for zipalertinib (Feb 27, 2027) is a longer-dated catalyst than the Phase 2 start.
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
Second-quarter operating expenses and net loss were lower than the same period in 2025, while the investment balance declined from December 31, 2025 and the investment case remains dependent on clinical, regulatory and partner milestones through 2026 and early 2027.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Research and development expensesGAAP | $ 44,437 | – | – |
| General and administrative expensesGAAP | 12,817 | – | – |
| Total operating expensesGAAP | 57,254 | – | – |
| Loss from operationsGAAP | (57,254) | – | – |
| Interest incomeGAAP | 3,648 | – | – |
| Other expense, netGAAP | (98) | – | – |
| Net lossGAAP | $ (53,704) | – | – |
| Research and development expenses, six months ended June 30GAAP | $ 86,560 | – | – |
| General and administrative expenses, six months ended June 30GAAP | 24,391 | – | – |
| Total operating expenses, six months ended June 30GAAP | 110,951 | – | – |
| Loss from operations, six months ended June 30GAAP | (110,951) | – | – |
| Interest income, six months ended June 30GAAP | 7,746 | – | – |
| Other expense, net, six months ended June 30GAAP | (160) | – | – |
| Net loss, six months ended June 30GAAP | $ (103,365) | – | – |
2026 and early 2027 outlook
- NoteCash resources are expected to provide runway into 2029 under the current operating plan.
- NoteAdditional CLN-978 multi-dose regimen data in rheumatoid arthritis are planned in Q3 2026.
- NoteInitial CLN-978 multi-dose regimen data in systemic lupus erythematosus are planned in Q4 2026.
- NoteInitial CLN-978 data from the single target dose escalation portion of the Sjögren’s disease study are planned in Q4 2026.
- NoteAdditional multi-dose velinotamig data are expected to be shared in Q4 2026.
- NoteA potentially registrational Phase 2 study of CLN-049 in relapsed/refractory AML will be initiated in Q3 2026.
- NoteAn update from the CLN-049 Phase 1 dose-escalation study is planned in Q4 2026.
- NoteA Phase 1/2 study of CLN-049 with venetoclax and azacitidine in previously untreated AML will be initiated in Q4 2026.
- NotePhase 2 expansion for CLN-978 in SLE, lupus nephritis and RA is planned for early 2027.
- NoteA global Phase 1/2 basket study of velinotamig in autoimmune cytopenias is planned for early 2027.
- NoteThe PDUFA target action date for zipalertinib is February 27, 2027.
- NoteTaiho expects top-line REZILIENT3 results by the end of 2026.
What drove it
- CLN-978 initial data in SLE and RA presented at the EULAR 2026 Congress and the Company’s Immunology Day event described deep, dose-dependent B cell depletion with a favorable safety profile.
- The Company reported a positive End-of-Phase 1 meeting with the U.S. FDA in July for CLN-049 and plans to initiate a potentially registrational Phase 2 study in relapsed/refractory AML in Q3 2026.
- Two patients with SLE and nephritis treated with multi-dose velinotamig in the Genrix Bio Phase 1/2 study in China achieved complete renal response, according to the Company.
- Taiho’s NDA for zipalertinib was accepted by the U.S. FDA in April for previously treated locally advanced or metastatic EGFR ex20ins NSCLC.
Concerns
- Cullinan reported a net loss and loss from operations for both the three months and six months ended June 30, 2026.
- Cash, cash equivalents, investments, and interest receivable declined from December 31, 2025.
- The pipeline remains in clinical development, with several anticipated data readouts, trial initiations and regulatory outcomes identified as future events.
- Zipalertinib economics are contingent on regulatory approvals and collaboration performance.
What to watch
- Additional CLN-978 multi-dose regimen data in RA in Q3 2026.
- CLN-978 SLE multi-dose data, CLN-978 Sjögren’s disease initial data, velinotamig multi-dose data and a CLN-049 dose-escalation update in Q4 2026.
- Initiation of the potentially registrational CLN-049 Phase 2 study in relapsed/refractory AML in Q3 2026.
- Taiho’s expected REZILIENT3 top-line results by the end of 2026 and the February 27, 2027 PDUFA target action date for zipalertinib.
- Planned CLN-978 Phase 2 expansions and the global velinotamig Phase 1/2 basket study in early 2027.
Balance sheet and cash flow
- Cash, cash equivalents, investments, and interest receivable were $ 355,967 as of June 30, 2026, compared to $ 438,960 as of December 31, 2025.
- Total assets were $ 363,787 as of June 30, 2026, compared to $ 448,374 as of December 31, 2025.
- Total current liabilities were $ 40,628 as of June 30, 2026, compared to $ 37,741 as of December 31, 2025.
- Total liabilities were $ 42,033 as of June 30, 2026, compared to $ 39,644 as of December 31, 2025.
- Total stockholders’ equity was $ 321,754 as of June 30, 2026, compared to $ 408,730 as of December 31, 2025.
Analysis
Cullinan reported lower operating expenses and a lower net loss for the second quarter of 2026 than in the same period in 2025. Research and development expenses were $ 44,437 versus $ 61,030, while general and administrative expenses were 12,817 versus 14,768. Total operating expenses were 57,254, loss from operations was (57,254), and net loss was $ (53,704). The filing does not report revenue, reflecting the company’s clinical-stage profile.
The six-month figures show the same expense and loss pattern. Research and development expenses for the six months ended June 30 were $ 86,560 compared with $ 102,489, and total operating expenses were 110,951 compared with 130,794. Net loss for the six-month period was $ (103,365) compared with $ (118,556). Interest income was lower in both reported periods than in the corresponding 2025 periods.
Liquidity remains central to the company’s operating plan. Cash, cash equivalents, investments, and interest receivable were $ 355,967 as of June 30, 2026, compared with $ 438,960 as of December 31, 2025. Total stockholders’ equity was $ 321,754 compared with $ 408,730. Management expects its cash resources to provide runway into 2029 under its current operating plan.
The near-term operating narrative is driven by clinical catalysts rather than commercial performance. The company plans additional CLN-978 RA data in Q3 2026, with multiple CLN-978, velinotamig and CLN-049 updates in Q4 2026. A positive End-of-Phase 1 meeting for CLN-049 supports the planned initiation of a potentially registrational Phase 2 study in relapsed/refractory AML in Q3 2026. The filing also identifies a February 27, 2027 PDUFA target action date for Taiho’s zipalertinib NDA and expected REZILIENT3 top-line results by the end of 2026.
The important watchpoints are execution against these data, study-start and regulatory timelines, as well as the cash balance as the pipeline advances into planned Phase 2 and global Phase 1/2 programs in early 2027. Cullinan is eligible to receive $30 million and up to $100 million upon 2L and 1L U.S. regulatory approvals, respectively, for zipalertinib, as well as a 50/50 profit share in the U.S., but these economics depend on the stated approvals.
Management, verbatim
At our recent Immunology Day event, we shared compelling initial clinical data for CLN-978 and velinotamig, two T cell engagers with potential to achieve immune reset and transform outcomes for people living with autoimmune diseases. We look forward to sharing additional clinical data throughout the remainder of 2026 as we rapidly advance these programs towards Phase 2 studies.
Nadim Ahmed, President and CEO of Cullinan Therapeutics
Additionally, following a positive End-of-Phase 1 meeting with the FDA in July, we will begin a potentially registrational Phase 2 study in patients with relapsed or refractory AML this quarter. CLN-049 represents a promising novel immunotherapeutic approach for a broad population of AML patients who currently have limited treatment options and poor prognosis.
Nadim Ahmed, President and CEO of Cullinan Therapeutics
Not in the filing
stated, not guessed- Revenue and revenue comparisons
- Segment revenue and segment comparisons
- Gross profit and gross margin
- Operating income
- Income tax expense or benefit and tax rate
- Basic and diluted net loss per share values, because the earnings-per-share line is truncated in the provided filing text
- Weighted-average shares outstanding
- Operating cash flow
- Free cash flow
- Debt and debt maturities
- Capital returns, including share repurchases and dividends
- Prior-quarter comparisons
- Percentage year-over-year and quarter-over-quarter changes
- Prior outlook for comparison
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This SEC Form 8-K (Item 2.02) accompanies Cullinan’s corporate update and Q2 2026 financial results, alongside pipeline and milestone timing for multiple T cell engager programs.
Ticker impact
Cullinan reports Q2 2026 financials and updates its T cell engager pipeline, including a potentially registrational AML Phase 2 start in Q3 2026 and cash runway into 2029.
Moderate upside bias on any risk-on reaction, with volatility around the Q3 2026 AML Phase 2 initiation and later multi-dose data readouts.
This is a primary SEC filing with concrete program timelines (Q3 2026 Phase 2 start, Q4 2026 data, early 2027 expansions) and a quantified cash position ($356M) supporting runway into 2029.
Market effects
Reinforces investor appetite for clinical-stage T cell engager platforms in immunology and oncology, especially where FDA milestones de-risk Phase 2 starts.
Limited direct regional spillover; primarily affects US small/mid-cap biotech sentiment.
International clinical progress is referenced (Genrix Bio Phase 1/2 in China), but the trading impact is mainly US-listed CGEM.
Counterpoint
Despite the FDA milestone, the article does not provide new efficacy endpoints for the AML Phase 2; timelines can slip and early data may not translate into registrational success.
Key entities
- issuerCullinan Therapeutics, Inc.
Nasdaq-listed clinical-stage biopharmaceutical company developing T cell engagers for autoimmune diseases and cancer.
- pipeline_programCLN-049 (FLT3 TCE)
Potentially registrational Phase 2 study in relapsed/refractory AML to begin in Q3 2026 after a positive FDA End-of-Phase 1 meeting.
- pipeline_programCLN-978 (CD19xCD3 TCE)
Multi-dose regimen data planned for Q3 2026 (RA) and Q4 2026 (SLE), with Phase 2 expansion early 2027.
- pipeline_programVelinotamig (BCMAxCD3 TCE)
Multi-dose regimen data expected in Q4 2026; global Phase 1/2 basket study in autoimmune cytopenias planned for early 2027.
- collaboration_programZipalertinib (EGFR ex20ins inhibitor)
NDA accepted by FDA; PDUFA target action date is Feb 27, 2027, with potential milestone and profit-share economics for Cullinan.
